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(08%), Incidences of acute coronary syndrome, accelerated hy-
pertension with or with out left ventricular failure and diabetic
emergencies.
Medical
emergencies
Counselled
group[4178]
Non-counselled
group[3761]
P value
Acute Cor Syndrome 37 51 0.005
STEMI 03 05 0.35
Hypertensive LVF 06 14 0.02
Diabetic Emergency 05 14 0.009
Acute coronary syndrome [NSTMI & STEMI] were 37 and 51
among the counseled and non-counseled groups were respec-
tively [p <0.005]. STEMI occurrences were non-significantly less in
counseled group. Hypertensive and Diabetic emergencies were
significantly low in counselled group [06 vs 14, p¼0.02 and 05 vs
14,p¼0.009].
Conclusions: Door step heart awareness program with active
participation though difficult but highly effective in preventing
major cardiac events and very helpful in identifying the asymp-
tomatic pattern of hypertension, diabetes and ischemic heart
diseases. Though it is a study in a small and confined area the
effect of the door step counselling definitely scores above the
passive program at the health centres. Larger studies by other
organizations are required to get better results.
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Background: To compare clinical characteristics, management
and outcomes between Middle East Arabs and Indian subconti-
nent acute heart failure (AHF) patients enrolled in the Gulf aCute
heArt failuRe rEgistry (Gulf CARE) study.
Methods: Data were analyzed from 4,539 consecutive AHF pa-
tients admitted during Feb.14, 2012 to Nov.14, 2012 in 47 hospitals
among 7 Middle East countries.
Results: The Middle Eastern Arab group (4157) was older (60 vs. 54
years; p<0.001), with high prevalence of coronary artery disease
(48% vs. 37%; p<0.001), valvular heart disease (14% vs. 7%;
p<0.001), atrial fibrillation (12% vs. 7%; p¼0.005) and khat chewing
(21% vs. 1%; p<0.001). Indian subcontinent patients (382) were
more likely to be smokers (36% vs. 21%; p<0.001), alcohol con-
sumers (11% vs. 2%; p<0.001) with high prevalence of diabetes
mellitus (56% vs. 49%; p¼0.011). AHF with reduced ejection
fraction (EF<40%) (76% vs. 65%; p<0.001) and ischemic heart dis-
ease (65% vs. 53%; p<0.001) as etiology were higher in Indian
subcontinent patients with valvular heart disease low in both
cohorts (9.3% vs. 5%; p<0.001). Acute coronary syndrome as
precipitating factor was more common in Indian subcontinent
patients (46% vs. 26%; p<0.001) as well as STEMI precipitating AHF
(26% vs. 9%; p<0.001). In-hospital mortality was 6.5% with no
difference, but 3-month mortality was significantly high among
Middle East Arabs when compared to Indian subcontinent pa-
tients (13.7% vs. 7.6%; p<0.003).
Conclusions: AHF patients from this region are a decade younger
than Western patients with high prevalence of ischemic heart
disease, diabetes, a higher preponderance to AHF with reduced
ejection fraction. Middle East Arabs were associated with higher
rates of heart failure risk factors. In-hospital mortality was
similar, but 3-month mortality was high in Middle East group.
There is an urgent need to prevent and control ischemic heart
disease and diabetes to reduce heart failure burden and mortality
among both groups.
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Background: Volume overload is the dominant feature of
decompensated heart failure (HF) and it often results in adverse
clinical Outcomes. Hyponatraemia and volume overload has
been reported to be a potent predictor of poor outcome in pa-
tients hospitalized for heart failure (HF). The aim of the study
was to determine the prevalence and prognostic significance of
hyponatraemia/eunatremia in a small subset of HF patients due
to any cause with reference to weight reduction and spot uri-
nary sodium and urinary osmolality and symptom class
improvement.
Methods: 25 patients with Heart failure admitted at a tertiary care
hospital were recruited in this observational study. Among them 6
were Eunatremic and 19were hyponatraemic. Bodyweight, serum
sodium, urinary sodium and urinary osmolality were measured at
admission and at one week after starting of TOLVAPTAN (HYPO-
NAT) 15 mg. Difference between body weight, serum sodium,
urinary sodium and urinary osmolality was analyzed by using
wilcoxon signed rank test.
Results: There was significant reduction in body weight (p
value<0.001, z¼ -3.611), serum sodium (p value<0.001, z ¼ -4.147),
urinary sodium (p value < 0.001, z ¼ -3.311) at follow up of 1 week.
There was no significant difference in urinary osmolality (p val-
ue¼ 0.106, z¼ -1.614). We also noted significant improvement in
symptoms in eunatremic patients (n¼6).
Conclusion: Tolvaptan acts as aqauretics without affecting uri-
nary sodium and urinary osmolality with reduction of body
weight and symptomatic improvement in heart failure patients.
The presence of hyponatraemia in outpatients with HF is associ-
ated with increased risk of hospitalization. Large scale trials are
required before recommending tolvaptan in eunatremic heart
failure.
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